New CDMO Amatsi-Avogadro formed

- Last updated on GMT

Related tags: Management

Amatsi and Avogadro have announced plans to team up and create what they claim will be the leading CDMO in France.

The new entity, named Amatsi Avogadro, will provide a range of development and analytical services as well as manufacturing, packaging and distribution services for clinical trials.

The firms generated combined turnover of €20m ($27.7m) in fiscal 2011 and together employ 175 staff at sites in Montpellier and Toulouse in France and Cambridge in the US.

Amatsi president Jean-Pascal Conduzorgues said teaming with Avogadro will provide “a larger range of facilities to our clients, increased development capabilities as well as a stronger quality assurance framework​.”

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more